Cognitive Health Company News

Results of the PRESTOCON preclinical trial are in

Cognitive Health Company News

Results of the PRESTOCON preclinical trial are in

The results of the PRESTOCON preclinical trial have demonstrated that Panax ginseng and Gingko biloba extracts have a well-documented safety profile and are well tolerated for the treatment of moderate-to-severe disease.

In addition, the trial provided useful insights into the application of Panax ginseng (G115) and Gingko biloba (GK501) as novel and natural therapeutic intervention for the treatment of cognitive-related diseases.

These findings support the idea that the combination may become a valid and safe therapeutic intervention in the treatment of neurological disorders.

Download the full article

Learn

Research is important, and we want to share it. Our articles distill the complex research and offer expert analysis on the microbiome, brain health and wellbeing.
Cognitive Health

How to feed your creativity in the age of AI

We’re using AI more than ever - but what does that mean for our creative minds? Here’s how to keep yours thriving.

Read more
Cognitive Health

An essential guide to cognitive rehabilitation

Research suggests cognitive rehabilitation may aid recovery and independence, especially when tailored to individual needs and conditions.

Read more
Cognitive Health

What influences healthy brain development in children?

Early childhood is a time of rapid brain growth. Learn how nutrition, sleep, and care shape lifelong cognitive development.

Read more